Literature DB >> 16760255

Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis.

V P van Halm1, M M J Nielen, M T Nurmohamed, D van Schaardenburg, H W Reesink, A E Voskuyl, J W R Twisk, R J van de Stadt, M H M T de Koning, M R Habibuw, I E van der Horst-Bruinsma, B A C Dijkmans.   

Abstract

BACKGROUND: Rheumatoid arthritis is characterised by inflammation and an increased cardiovascular risk. It was recently shown that active early rheumatoid arthritis is associated with dyslipidaemia, which may partially explain the enhanced cardiovascular risk. However, it is unknown when this dyslipidaemia starts.
OBJECTIVE: To investigate the progression of the lipid profile over time and the influence of inflammatory parameters on this lipid profile, in people who later developed rheumatoid arthritis.
METHODS: Levels of total cholesterol, high-density lipoprotein cholesterol (HDLc), triglycerides, apolipoprotein AI (apo AI), apolipoprotein B (apo B) and lipoprotein(a) (Lp(a)) were determined in 1078 stored, deep-frozen, serial blood bank samples, collected between 1984 and 1999, of 79 blood donors who later developed rheumatoid arthritis. These samples were compared with 1071 control samples of unselected blood donors, matched for age, sex and storage time.
RESULTS: Samples of patients who later developed rheumatoid arthritis showed, on average, 4% higher total cholesterol, 9% lower HDLc, 17% higher triglyceride and 6% higher apo B levels than matched controls (p< or =0.05). The magnitude of the differences in lipid levels between groups, explained by C reactive protein (CRP), was limited. For example, only 3.6% of the difference in HDLc levels between the groups was explained by the CRP concentrations.
CONCLUSION: Patients who later develop rheumatoid arthritis have a considerably more atherogenic lipid profile than matched blood donors at least 10 years before onset of symptoms. As inflammation only marginally explains the differences between the two groups, a modulating effect of lipids on inflammatory processes is hypothesised.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760255      PMCID: PMC1798498          DOI: 10.1136/ard.2006.051672

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  35 in total

Review 1.  Multilevel modelling of medical data.

Authors:  Harvey Goldstein; William Browne; Jon Rasbash
Journal:  Stat Med       Date:  2002-11-15       Impact factor: 2.373

2.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

Authors:  G Walldius; I Jungner; I Holme; A H Aastveit; W Kolar; E Steiner
Journal:  Lancet       Date:  2001-12-15       Impact factor: 79.321

3.  Coronary risk factors predicting early and late coronary deaths.

Authors:  A Menotti; M Lanti
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

4.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

Authors:  Hyon K Choi; Miguel A Hernán; John D Seeger; James M Robins; Frederick Wolfe
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

5.  Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

6.  Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.

Authors:  Nicola J Goodson; Nicola J Wiles; Mark Lunt; Elizabeth M Barrett; Alan J Silman; Deborah P M Symmons
Journal:  Arthritis Rheum       Date:  2002-08

7.  Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.

Authors:  Yong-Beom Park; Hyon K Choi; Min-Young Kim; Won-Ki Lee; Jungsik Song; Dong-Kee Kim; Soo-Kon Lee
Journal:  Am J Med       Date:  2002-08-15       Impact factor: 4.965

Review 8.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study).

Authors:  Johannes Hulthe; Björn Fagerberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-07-01       Impact factor: 8.311

10.  Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis.

Authors:  S Rantapää-Dahlqvist; S Wållberg-Jonsson; G Dahlén
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

View more
  65 in total

1.  Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.

Authors:  Jeffrey R Curtis; Ani John; Onur Baser
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-09       Impact factor: 4.794

2.  Serum Lipid Alterations in Early Rheumatoid Arthritis Patients on Disease Modifying Anti Rheumatoid Therapy.

Authors:  Sana Parveen; Rachel Jacob; Liza Rajasekhar; C Srinivasa; Iyyapu Krishna Mohan
Journal:  Indian J Clin Biochem       Date:  2016-04-22

Review 3.  Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm.

Authors:  Jamie Robertson; Mike J Peters; Iain B McInnes; Naveed Sattar
Journal:  Nat Rev Rheumatol       Date:  2013-06-18       Impact factor: 20.543

4.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

Review 5.  Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.

Authors:  Katherine P Liao; Daniel H Solomon
Journal:  Rheumatology (Oxford)       Date:  2012-09-16       Impact factor: 7.580

6.  Apolipoprotein a-I at the interface of vascular inflammation and arthritis.

Authors:  Robert Terkeltaub
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-03       Impact factor: 8.311

7.  Modulation of autoimmune arthritis severity in mice by apolipoprotein E (ApoE) and cholesterol.

Authors:  P Alvarez; F Genre; M Iglesias; J J Augustin; E Tamayo; J C Escolà-Gil; B Lavín; F Blanco-Vaca; R Merino; J Merino
Journal:  Clin Exp Immunol       Date:  2016-10-04       Impact factor: 4.330

8.  Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis.

Authors:  C Trocmé; H Marotte; A Baillet; B Pallot-Prades; J Garin; L Grange; P Miossec; J Tebib; F Berger; M J Nissen; R Juvin; F Morel; P Gaudin
Journal:  Ann Rheum Dis       Date:  2008-07-29       Impact factor: 19.103

Review 9.  High-density lipoprotein affects antigen presentation by interfering with lipid raft: a promising anti-atherogenic strategy.

Authors:  S-H Wang; S-G Yuan; D-Q Peng; S-P Zhao
Journal:  Clin Exp Immunol       Date:  2010-01-06       Impact factor: 4.330

10.  Association between low density lipoprotein and rheumatoid arthritis genetic factors with low density lipoprotein levels in rheumatoid arthritis and non-rheumatoid arthritis controls.

Authors:  Katherine P Liao; Dorothée Diogo; Jing Cui; Tianxi Cai; Yukinori Okada; Vivian S Gainer; Shawn N Murphy; Namrata Gupta; Daniel Mirel; Ashwin N Ananthakrishnan; Peter Szolovits; Stanley Y Shaw; Soumya Raychaudhuri; Susanne Churchill; Isaac Kohane; Elizabeth W Karlson; Robert M Plenge
Journal:  Ann Rheum Dis       Date:  2013-05-28       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.